Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02794883
Title Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Northwestern University
Indications

high grade glioma

Therapies

Tremelimumab

Durvalumab + Tremelimumab

Durvalumab

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Northwestern University Chicago Illinois 60611 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field